Adval Tech Holding AG

Latest Results (27.07.2026):

Adval Tech Holding AG — first half of 2025 (covering Q1–Q2 2025): the Group reported total income of CHF 79.5 million and net turnover of CHF 77.7 million, with EBITDA of CHF 0.8 million and an operating result (EBIT) of CHF -2.2 million. The net result was CHF -4.7 million. Free cash flow improved to CHF 2.2 million versus a large negative in H1 2024. Results were weighed down by a challenging automotive market, extraordinary effects including a cyber attack, and currency/headwind effects, while the company progressed on its forward strategy and won significant medtech and automotive contracts.

Key numbers

Total income CHF 79.5m (−11.9% vs H1 2024); net turnover CHF 77.7m (−8.9%). EBITDA CHF 0.8m (0.9% of total income) vs CHF 3.5m in H1 2024; EBIT CHF −2.2m (−2.8%); net result CHF −4.7m. Adjusted for currency effects: EBITDA CHF 1.0m, EBIT CHF −2.0m. Extraordinary item related to the cyber attack: CHF −0.6m.

Cash flow and investments

Cash flow from operations improved to CHF 4.5m (H1 2024: CHF −9.7m). Free cash flow turned positive at CHF 2.2m (H1 2024: CHF −12.4m), largely due to returns from prior pre-financing of toolmaking projects. Capital expenditure remained modest at CHF 2.4m.

Balance-sheet position

Liquid assets CHF 14.7m at 30 June 2025. Operating net current assets were CHF 50.8m (inventory, receivables, payables) and averaged 33.2% of total income. Interest-bearing liabilities reduced to CHF ~6.7m (short + long), partly paid down with tooling receipts.

Market and regional mix

Europe remains dominant (69% of sales), Asia 11%, Latin America 15%, North America 5%. Automotive demand was weak (notably at Swiss and German sites), while Brazil, plastics sites (Hungary, Mexico, China) and tools business showed pockets of strength. Medtech sales outperformed expectations and the Group secured sizable new orders.

Extraordinary events — cyber attack and U.S. tariffs

Adval Tech experienced a cyber attack on 2 March 2025; production was maintained and the incident resolved within weeks. Direct and indirect costs were in the high six-figure range (extraordinary result CHF −0.6m). New U.S. import tariffs negatively affected exports and led to the discontinuation of a project at the Endingen (DE) plant, causing a multi‑million CHF revenue shortfall in 2025.

Forward strategy and outlook

Management reports progress on its forward strategy (organizational changes, performance reporting, operational adjustments). The Group expects improved profitability in H2 2025, continued focus on medtech growth and targeted structural measures to respond to short‑term automotive volatility while accelerating medtech expansion.

Management and workforce

At the AGM (15 May 2025) Dirk Lambrecht was elected Chairman and Jörg Buchheim joined the Board; Ralf Eble became COO (from 1 May 2025). Headcount rose to 1,102 FTEs (up from 1,085 at year-end 2024), driven mainly by temporary hires for ramp-ups and quality initiatives in Mexico.